The DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.
A supportive care intervention for people with metastatic melanoma being treated with immunotherapy: a pilot study assessing feasibility, perceived benefit, and acceptability
Abstract
Introduction: Increasing numbers of metastatic melanoma (MM) patients are receiving immunotherapy treatment, including pembrolizumab, and the impact on their well-being is underexplored. Objectives: To assess the feasibility of a multimodal supportive care program to MM patients being treated with pembrolizumab. Methods: This pre-post-test feasibility cohort study recruited MM participants treated with pembrolizumab: (i) supportive care intervention with usual care and (ii) usual care. The intervention comprised comprehensive medical assessment by supportive care physician (SCP), exercise physiologist (EP), and dietitian then a tailored supportive care program. Programs included exercise, dietary advice, non-invasive complementary therapies, and psychology consultation. Outcome measures included adherence, patient-reported symptoms, anxiety and depression, and toxicity. Descriptive data are reported. Results: We recruited 28 participants: 13 intervention and 15 control; three did not complete the study. Most were male, with median age 66 (range 42–85) years. All intervention participants completed baseline assessments with SCP, EP, and dietitian. Two missed follow-up with EP or dietitian. Symptoms most troubling at baseline were as follows: fatigue (n = 6), sleep (n = 6), general aches and pains (n = 5), and memory (n = 4). All intervention participants were prescribed 16 exercise sessions; 8 (50%) completed all; overall exercise adherence was 85%. Integrative therapies were accessed by 85% (11) participants. Immunotherapy-related adverse event rates were low and SCP consultation identified symptoms not captured by CTCAE 4.0. Conclusions: A holistic supportive care intervention tailored to individual needs is feasible. The symptom burden in MM patients was low. Further investigation of the intervention is warranted, focused on populations with higher symptom burden to improve outcomes. © 2018, Springer-Verlag GmbH Germany, part of Springer Nature.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
The Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer
Temel, J. S., Greer, J. A., Muzikansky, A., Gallagher, E. R., Admane, S., Jackson, V. A., Dahlin, C. M., Blinderman, C. D., Jacobsen, J., Pirl, W. F., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000678 · Cited by 7,482
The functional assessment of cancer therapy scale: development and validation of the general measure
Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., Silberman, M., Yellen, S. B., Winicour, P., & Brannon, J. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.570 · Cited by 6,020
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Self-citationOverall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357
Schachter, J., Ribas, A., Long, G. V., Arance, A., Grob, J.-J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31601-x · Cited by 1,225
Self-citationExercise for the management of cancer-related fatigue in adults
Cramp, F., & Byron-Daniel, J. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006145.pub3 · Cited by 1,096
Cancer-Related Fatigue, Version 2.2015
Berger, A. M., Mooney, K., Alvarez-Perez, A., Breitbart, W. S., Carpenter, K. M., Cella, D., Cleeland, C., Dotan, E., Eisenberger, M. A., Escalante, C. P., et al. (2015) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2015.0122 · Cited by 949
Kotronoulas, G., Kearney, N., Maguire, R., Harrow, A., Di Domenico, D., Croy, S., & MacGillivray, S. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.5948 · Cited by 946
Research works printed but not linked: 1
- Office QoL (2018) Calculating nom-based T-scores from your FACT-G data. POCOG, University of Sydney, Sydney Available from: www.pocog.org.au/pod/factgscores.aspx
Cited by
Deshpande, R. P., Sharma, S., & Watabe, K. (2020) · Cancers · doi:10.3390/cancers12102983 · Cited by 107
“Low symptom burden Not clear Metastatic melanoma – [95]”
BackgroundLi, H., Wong, C. L., Jin, X., Chen, J., Chong, Y. Y., & Bai, Y. (2021) · International Journal of Nursing Studies · doi:10.1016/j.ijnurstu.2021.103876 · Cited by 81
Levy, D., Dhillon, H. M., Lomax, A. J., Marthick, M., McNeil, C. M., Kao, S. C.-H., & Lacey, J. (2018) · Supportive Care in Cancer · doi:10.1007/s00520-018-4443-3 · Cited by 69
Self-citationKolsteren, E. E. M., Deuning‐Smit, E., Chu, A. K., van der Hoeven, Y. C. W., Prins, J. B., van der Graaf, W. T. A., van Herpen, C. M. L., van Oort, I. M., Lebel, S., Thewes, B., et al. (2022) · Cancers · doi:10.3390/cancers14163889 · Cited by 77
“The EuroQol 5D (EQ-5D; n = 11), the 36- or 12-item Short-Form Health Survey (SF-36; SF-12, n = 6), the Edmonton Symptom Assessment System (ESAS); n = 2), the Assessment of Quality of Life (AQol-8D; n = 1), the Cancer Institute Quality of Life Questionnaire (CI-QOL-Q; n = 1), the Functional Assessment of Chronic Illnes…”
Thomsen, S. N., Lahart, I. M., Thomsen, L. M., Fridh, M. K., Larsen, A. T. S., Mau‐Sørensen, M., Bolam, K. A., Fairman, C. M., Christensen, J. F., & Simonsen, C. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.101937 · Cited by 67
Metadata
- Authors
- Lacey, J., Lomax, A. J., McNeil, C., Marthick, M., Levy, D., Kao, S., Nielsen, T., & Dhillon, H. M.
- Affiliations
- The University of Sydney (AU)
- Chris O’Brien Lifehouse (AU)
- Corresponding author
- Lacey, Judith
- Venue
- Supportive Care in Cancer
- Published
- 2018-11-03
- Volume
- 27
- Issue
- 4
- Pages
- 1497-1507
- ISSN
- 0941-4355 (ISSN-L)
- 1433-7339
- OpenAlex
- W2898934815
- Cited by
- 42
- References
- 38
- Citations by year
- 2025: 9 · 2024: 4 · 2023: 10 · 2022: 8 · 2021: 4 · 2020: 5 · 2019: 1 · 2018: 1
- FWCI
- 1.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Supportive Care in Cancer (publishedVersion)
- PubMed (publishedVersion)
- Funders
- MSD Ltd (N/A)
- Topics
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Health Sciences › Medicine › Complementary and alternative medicine › Complementary and Alternative Medicine Studies
- Keywords
- metastatic melanoma, pembrolizumab, immunotherapy, supportive care, exercise intervention, dietary recommendations, integrative therapy, symptom burden, fatigue, anxiety and depression, immunotherapy toxicity, feasibility, patient-reported outcomes, holistic care
- MeSH terms
- Adult, Aged, Aged, 80 and over, Combined Modality Therapy, Diet Therapy, Exercise Therapy, Feasibility Studies, Female, Humans, Immunotherapy, Male, Melanoma, Middle Aged, Neoplasm Metastasis, Palliative Care, Patient Acceptance of Health Care, Perception, Pilot Projects, Quality of Life, Cohort Studies, Risk Assessment, Musculoskeletal Manipulations, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A supportive care intervention for people with metastatic melanoma being treated with immunotherapy: a pilot study assessing feasibility, perceived benefit, and acceptability. https://app.cochat.ai/papers/10.1007/s00520-018-4524-3
- The paper
- Lacey, J., Lomax, A. J., McNeil, C., Marthick, M., Levy, D., Kao, S., Nielsen, T., & Dhillon, H. M. (2019). A supportive care intervention for people with metastatic melanoma being treated with immunotherapy: a pilot study assessing feasibility, perceived benefit, and acceptability. Supportive Care in Cancer. https://doi.org/10.1007/s00520-018-4524-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.